Genedrive Regulatory News (GDR)

genedrive plc ("genedrive" or "the Company")

 Total Voting Rights

In accordance with the FCA's Disclosure Guidance and Transparency Rules, the Company wishes to notify the market of the following:

As at 29 June 2018, the Company's issued share capital consisted of 18,783,115 ordinary shares of 1.5 pence each ("Ordinary Shares"), all with voting rights. No shares are currently held in treasury. The total number of voting rights in the Company as at 29 June 2018 is therefore 18,783,115.

The above figure (18,783,115 Ordinary Shares) may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in the Company.

- Ends -

For further details please contact:

genedrive plc

David Budd: CEO +44 (0)161 989 0245

Matthew Fowler: CFO

Peel Hunt LLP

James Steel +44 (0)207 418 8900

Oliver Jackson

Consilium Strategic Communications

Chris Gardner +44 (0)203 709 5700

Matthew Neal

Laura Thornton

genedrive@consilium-comms.com 

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID test has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA  and SE Asia (ex India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV ID Kit and Genedrive® platform in India.

Further details can be found at: www.genedriveplc.com and www.genedrive.com